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Abstract 
Hydroxyethyl starch (HES) solutions have mainly been indicated as "volume 
expanders". Recent unfavorable reports of these solutions such as probability of 
kidney injury or inducing coagulopathy have relatively ejected these solutions 
in many centers, particularly in European countries. Despite several confirming 
studies, multiple anecdotal letters or reviews has challenged total disappearance 
of these colloids from medicine practice. In addition, some novel observations 
emphasized to distinguished ability of HES to preserve the microvascular 
integrity even at the presence of an inflammatory process. Despite extreme 
statements has been published demanding immediate suspension of these fluids 
from the market, it seems logical to revise the most recent studies which may 
declare new pathways to approach HES family of solutions. 
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Hydroxyethyl starch (HES) solutions were 
introduced 8 decades ago, rapidly gained popularity in 
critical situations such as intensive care units or 
veterinary hospitals. They have become one of the 
pillars of fluid resuscitation, primarily in emergency 
hypovolemic situations. Since 2013 different 
communities have been exclaiming recommendations 
to suspend marketing of HES solutions (1-3). In less 
than ten years, HES usage has dropped crucially and 
this modification tends to be center-located which can 
be indicative of localized decision-making. Whether 
this downfall is logical or not, an overview of ideas 




During the last decade, an escalating obsession 
on HES-induced renal injury has arisen, especially 
within critical conventions (4-7). In the largest meta-
analysis by Cochrane Database including 142 studies 
and 11,399 patients of different populations, all HES 
products were blamed to increase the risk of acute 
kidney injury and renal replacement therapy (RRT). In 
addition it was concluded that no safe volume of any 
HES solution has been approved till the publication 
time in 2013 (8). This was the beginning for many 
other clinical trials searching for declaration of the 
truth. Five years later, in another reported by Cochrane 
(9), starches were compared to other fluids in 
resuscitation of critically ill patients. This time, slight 
increase in RRT rate was described, while, no 
difference to mortality was observed. 
Even so, anecdotal advices do not endorse such 
intense disapproval of HES. The most significant 
protest to withdrawal of all colloids from medicine 
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practice are published in the Lancet (10) and 
Anesthesia-Analgesia (11) journals just recently. In 
addition, recent studies on animal or non-septic human 
observed no kidney injury following HES 
administration (12, 13). Related to the present data, it 
seems practical to choose these types of fluids 
cautiously in critically ill patients or the ones at higher 
risk for kidney injury (11). However, it would be 




Li et al. reported decrease in platelet count in 
pediatric intensive care unit (ICU) patients. Although, 
in this meta-analysis, activated partial thromboplastin 
time or blood loss showed no significant difference 
within the given setting (14). Same results were 
reported by others as changes in clot structure 
(15),increased thrombine-antithrombine complex 
levels (16),or facilitation of clot initiation (17). Despite 
all, in a human randomized clinical trial (RCT) study 
on patients undergoing craniotomy for tumor resection, 
20 cc.kg-1 of HES 130/0.4 did not change 
thromboelstographic findings compared to 5% human 
albumin (18). Other study described the same results 
(19). Controversial observation on coagulation effects 




Different organs profit from perioperative HES 
administration. Ghodraty and colleagues reported 
improvement of intestinal motility and shortened 
duration of ileus after gastrointestinal operations in 
patients who received 6% hydroxyethyl starch to 
replace intraoperative fluid losses (20). Significant 
decrease in anastomotic leakage was observed 
following abdominal major surgery when colloids 
were given intraoperatively (21, 22), confirming 
previous beneficial findings.  
One of the most interesting studies on HES 
mechanism of action has manifested protective effects 
on vascular glycocalyx integrity (23). In this 2018 
interventional trial on animal model of inflammation, 
vascular permeability of the lungs, liver, kidney, and 
brain was measured by Evans blue extravasation. Both 
types of systemic and inhalational inflammation were 
induced which resulted in increased vascular 
permeability in mentioned organs. 6% HES 130/0.4 
infusion led to significantly preserved glycocalyx 
thickness in lung capillaries. This is the most precisely-
explained subcellular mechanism for HES 
intravascular end results. 
Through the last two decades, the role of 
glycocalyx in vascular functioning has been 
determined. The endothelial glycocalyx is a 
carbohydrate-rich layer connected to the endothelium 
of vessels via several types of proteoglycans. On its 
luminal site, it is consisted of plasma elements bonded 
via soluble glycosaminoglycans. This living layer 
interacts with the blood actively. The blood flow itself, 
constantly alters the composition and the thickness of 
the glycocalyx layer (24, 25).  
This bidirectional process is a dynamic 
equilibrium dictating the ability of endothelium as a 
“gatekeeper” (26). The permeability of glycocalyx is 
directly affected by the changes in the flow, turbulence 
or the composition of the blood. In hemorrhagic animal 
models, increased permeability of the endothelium due 
to glycocalyx shedding is reported. Resuscitation with 
different fluids has shown to have variable impacts. 
While normal saline resuscitation has the worst results 
(reduced glycocalyx thickness and increase in 
microvascular permeability), HES and albumin 
somehow preserved the endothelial stabilization (27). 
Although, HES and albumin control the extravasation 
of fluids via distinct mechanisms.(28) Further 
subcellular studies are in immediate need to answer our 
many substantial questions. 
Discussion 
Our knowledge about HES utilization in 
perioperative medicine is not complete yet. One of the 
main considered fields in fluid management inside and 
or outside the operating theater is to keep the infused 
fluid "inside" the circulatory system. Colloids, and in 
particular HES solutions, appear to be superior in some 
conditions. As scientists and academicians, we are 
obliged to ask questions about specific situations that 
each drug behave in our favor. Early, aggressive 
decisions may deprive us from beneficial products for 
years until resurrection of them by an unbiased 
physician, as happened before for many other 
medications. Reporting bias is described in the form of 
retraction of studies could be considered as one of 
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many reasons to question the available results (29). 
In some perioperative fields the principal focus 
has been on the probable side effects rather than 
advantages. For instance, in neurosurgical patients 
several studies assessed the plausible coagulopathy or 
renal dysfunction (13, 18), while scarcely any has 
reviewed their impacts on permeability of blood brain 
barrier despite reported benefits as osmotic agents in 
treatment of increased intracranial pressure (30). In 
summation HES might be beneficial in situations 
where increased vascular permeability and the 
increased transcapillary leakage of plasma fluid 
accompanies hypovolemia, and interstitial edema 
formation as observed in the mentioned 2018 study 
(23).This field is also quite appealing for researchers in 
the perioperative field.  
In addition, several studies detected different 
profile based on starches' molecular weights (31, 32), 
which can be defined in the importance emphasis of 
selection of patient or fluid. For instance, during acute 
normovolemic hemodilution, high-molecular-weight 
HES (650/0.42) disturbed hemostasis more than low-
molecular-weight HES (130/0.42). Besides, HES 
650/0.42 was reported to restore plasma volume less 
efficiently (33). Differentiation between the types of 
HES solutions may be the key to overcome the 
unwanted presentations and generating a smarter 
remedy.    
Conclusion 
We should justify the hazards of HES in 
septic patients or others in the risk of 
nephrotoxicity. Nevertheless, examining these 
fluids in situations which they are put in 
application anecdotally is yet incomplete. It is 
rational to be open to further molecular studies 
to find the relevant mechanisms for these 
solutions to make them profitable while 
subtracting unwanted adverse effects. 
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